CClinicalTrials.gg
RecruitingNCT06084143DSL-Covid-19Updated Oct 16, 2023

Analysis of Suicide Dynamics in Link to the COVID-19 Pandemic

An observational study in COVID-19, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-16.

Sponsored by University Hospital, Strasbourg, France · Observational

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 2 months later.
Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
2,500
Ages
18 Years and older
Sex
All
01

Study summary

Covid is a virus that first appeared in China in 2019 and was quickly described as a pandemic virus by its globalized nature. The unprecedented occurrence of the virus has led to several health and restrictive government measures. The Covid-19 pandemic and health measures have been able to contribute to the deterioration of the mental health of citizens as it has already been observed during the former pandemic context (Sars covid in 2003 in China or the Spanish flu).

Among the consequences of a negative impact on mental health, investigators assume that there is an increase in transitions to the completed suicidal act. However, current studies and observations tend to note that there has been no major change in the dynamics of successful suicides during the Covid period.

However, there are biases in the studies conducted: some suicide deaths may have been hidden and not reported as such, due to several factors. For example, the measure of the evolution of suicide attempts that was most often made by the measure of the evolution of the number of hospitalizations for this reason can be a source ofestimate whether people who did this gesture were not hospitalized after a visit to the emergency room or if they gave up attending because of the pandemic. Moreover, suicide deaths are more difficult to report as such when they occur at home than after hospitalization.

It is therefore interesting to study the dynamics of suicide during this health crisis retrospectively based on data from the Strasbourg Institute of Forensic Medicine containing the census of the Alsace region, which was hit hard by the pandemic.

02

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • Covid-19
  • Suicide
03

In context

COVID-19

7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.

This study's planned enrollment of 2,500 is above the median of 261 across 3,136 observational studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 966 studies on the registry; 342 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Adult patient died between 01/01/2018 and 12/31/2021

Inclusion criteria

  • Adult patient
  • Died between 01/01/2018 and 12/31/2021
  • Absence of opposition from the patient expressed in writing during his lifetime to the reuse of his personal data for scientific research purposes.

Exclusion criteria

Exclusion Criteria:

  • Presence of opposition by the patient expressed in writing during his lifetime to the reuse of his personal data for scientific research purposes.
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
2,500 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Suicide rates before and after the Covid-19 pandemic

    Time frame: from January 1, 2018 to December 31, 2021

07

Study locations

1 of 1 sites recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06084143
Lead sponsor
University Hospital, Strasbourg, France
Responsible party
Sponsor
First posted
Oct 16, 2023
Start date
Jul 21, 2023
Primary completion
Jul 21, 2024 (estimated)
Completion
Jul 21, 2024 (estimated)
Last update
Oct 16, 2023

Study contacts

Philippe MEYER, MD
Contact
philippe.meyer@chru-strasbourg.fr
33 3 88 11 16 48

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion